Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $518 | In Stock | |
10 mg | $828 | In Stock |
Description | Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interaction between EGFL7 and endothelial cells, and has an inhibitory effect on endothelial growth factor (VEGF).Parsatuzumab has been used in combination with other compounds for a long time. Combined use to study rectal cancer |
In vitro | EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival[2]. Against patient-derived xenograft (PDX) cells, Parsatuzumab inhibits cell proliferation and increases apoptosis after 48 hours[1]. |
In vivo | In several xenograft and genetically engineered murine tumor models, Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy[1].In mouse models of mantle cell lymphoma (MCL), Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7, inhibits MCL cell growth, and prolongs survival[1]. |
Alias | RG 7414, Anti-EGFL7, MEGF0444A, MEGF-0444A, RO-5490248, M0444A |
Cas No. | 1312797-14-0 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.